Angiotensin in progressive renal diseases: Theory and practice

Journal of the American Society of Nephrology

Volumn 7, Issue 10, 1996, Pages 2025-2043

  Matsusaka, Taiji ^a   Hymes, Jeffrey ^a   Ichikawa, Iekuni ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b MCN   (United States)

Author keywords

Extracellular matrix; Glomerulosclerosis; Interstitial fibrosis; Polymorphism; TGF

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METALLOPROTEINASE; ZOFENOPRIL;

DISEASE ASSOCIATION; DRUG EFFECT; EXTRACELLULAR MATRIX; GLOMERULOSCLEROSIS; IMMUNE SYSTEM; KIDNEY FIBROSIS; MESANGIUM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR ENDOTHELIUM;

EID: 0030392342     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (245)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
2. Bjôrck S, Mulec H, Johnsen SA, Norden G, Aurell M: Renal protective effect of enalapril in diabetic nephropathy. Br Med J 1992;304:339-343.
3. Cattran DC, Greenwood C, Ritchie S: Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 1994;23:247-254.
4. Rekola S, Bergstrand A, Bucht H: Deterioration rate in hypertensive IgA nephropathy: Comparison of a converting enzyme inhibitor and beta-blocking agents. Nephron 1991;59:57-60.
5. Terada Y, Tomita K, Nonoguchi H, Marumo F: PCR localization of angiotensin II receptor and angiotensinogen mRNA in rat kidney. Kidney Int 1993;43:1251-1259.
6. Kakinuma Y, Fogo A, Inagami T, Ichikawa I: Intrarenal localization of angiotensin II type 1 receptor mRNA in the rat. Kidney Int 1993;43:1229-1235.
7. Tufro-McReddie A, Harrison JK, Everett AD, Gomez RA: Ontogeny of type 1 angiotensin II receptor gene expression in the rat. J Clin Invest 1993;91:530-537.
8. Gasc J, Shanmugam S, Sibony M, Corvol P: Tissue-specific expression of type 1 angiotensin II receptor subtypes. An in situ hybridization study. Hypertension (Dallas) 1994;24:531-537.
9. Kakuchi J, Ichiki T, Kiyama S, et al.: Developmental expression of renal angiotensin II receptor genes in the mouse. Kidney Int 1995;47:140-147.
10. Ciuffo GM, Viswanathan M, Seltzer AM, Tsutsumi K, Saavedra JM: Glomerular angiotensin II receptor subtypes during development of the kidney. Am J Physiol 1993;265:F264-F271.
11. Lo M, Liu KL, Lantelme P, Sassard J: Subtype 2 of angiotensin II receptors controls pressure-natriuresis in rats. J Clin Invest 1995;95:1394-1397.
12. Nakajima M, Mukoyama M, Pratt RE, Horiuchi M, Dzau VJ: Cloning of cDNA and analysis of the gene for mouse angiotensin II type 2 receptor. Biochem Biophys Res Commun 1993;197:393-399.
13. Rosenberg ME, Smith LJ, Correa-Rotter R, Hostetter TH: The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int 1994;45:403-410.
14. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;77:1993-2000.
15. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-1930.
16. Anderson S, Diamond JR, Karnovsky MJ, Brenner BM: Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome. J Clin Invest 1988;82:1757-1768.
17. Yoshida Y, Kawamura T, Ikoma M, Fogo A, Ichikawa I: Effects of antihypertensive drugs on glomerular morphology. Kidney Int 1989;36:626-635.
18. Anderson S, Rennke HG, Garcia DL, Brenner BM: Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989;36:526-536.
19. Yasuda T, Becker B, Kondo S, Vaikunth S, Homma T, Harris RC: Mechanical stretch/relaxation increases type 1 angiotensin II receptor expression and angiotensinogen mRNA in cultured rat mesangial cells [Abstract]. J Am Soc Nephrol 1994;5:554.
20. Miyazaki Y, Kawamura T, Yoshida H, et al.: Static stretch enhances angiotensinogen and angiotensin converting enzyme gene expressions in glomerular endothelial cells [Abstract]. J Am Soc Nephrol 1995;6: 802A.
21. Owens GK: Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats. Hypertension (Dallas) 1987; 9:178-187.
22. Linz W, Schølkens BA, Ganten D: Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens 1989;11:1325-1350.
23. Clozel JP, Kuhn H, Hefti F: Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. J Hypertens 1989;7:267-275.
24. Akahoshi M, Carretero OA: Body fluid volume and angiotensin II in maintenance of one-kidney, one clip hypertension. Hypertension (Dallas) 1989;14:269-273.
25. Powell JS, Clozel JP, Müller RKM, et al.: Inhibitions of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science (Washington DC) 1989;245:186-188.
26. Wang DH, Prewitt RL: Captopril reduces aortic and microvascular growth in hypertensive and normotensive rats. Hypertension (Dallas) 1990;15:68-77.
27. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A: Blood pressure-independent effect of angiotensin inhibition on glomerular and nonglomerular vascular lesions of chronic renal failure. Kidney Int 1992;42:46-55.
28. Hebert LA, Bain RP, Verme D, et al.: Remission of nephrotic range proteinuria in type I diabetes. Kidney Int 1994;46:1688-1693.
29. Ritz E, Fuser D, Siebels M. Diabetic nephropathy. In: Massry SG, Glassock RJ Jr, Eds. Textbook of Nephrology. 3rd Ed. Baltimore: Williams & Wilkins; 1995:894-912.
30. Julian B, van den Wall Bake AWL. IgA nephropathy. In: Massry SG, Glassock RJ Jr, Eds. Textbook of Nephrology. 3rd Ed. Baltimore: Williams & Wilkins; 1995:752-764.
31. Guidi E, Magni M, di Belgiojoso GB, Minetti L, Bianchi G: Blood pressure in patients with four different primary glomerulopathies. Clin Exp Hypertens Part A Theory Pract 1984;6:1357-1366.
32. Kurokawa K, Brenner BM (presenters): Satellite Symposium of the 13th International Congress of Nephrology, Barcelona, July 7-8, 1995. In: Kurokawa K, Rodicio JL, Brenner BM. Hypertension: Causes and Consequences of Renal Injury. Kidney Int 1996; 49 [Suppl 55]: S1-S186.
33. Farquhar MG, Palade GE: Functional evidence for the existence of a third cell type in the renal glomerulus: Phagocytosis of filtration residues by a distinctive "third" cell. J Cell Biol 1962;13:55.
34. Singhal PC, Ding GH, DeCandido S, Franki N, Hays RM, Schlondorff D: Endocytosis by cultured mesangial cells and associated changes in prostaglandin E2 synthesis. Am J Physiol 1987;252:F627-F634.
35. Singhal PC, Santigo A, Striano J, Hays RM, Shlondorff D: Effects of vasoactive agents on uptake of immunoglobulin G complexes by mesangial cells. Am J Physiol 1990;258:F589-F596.
36. Sterzel RB, Lovett DH, Stein HD, Kashgarian M: The mesangium and glomerulonephritis. Klin Wochenschr 1982;60:1077-1094.
37. Stein HD, Feddergreen W, Kashgarian M, Sterzel RB: Role of angiotensin II-induced renal functional changes in mesangial deposition of exogenous ferritin in rats. Lab Invest 1983;49:270-280.
38. Raij L, Keane WF: Glomerular mesangium: Its function and relationship to angiotensin II. Am J Med 1985; 79[Suppl 3C]:24-30.
39. Dezsö B, Fóris G: Effect of angiotensin II on the Fc receptor activity of rat macrophages. Immunology 1981;42:277-283.
40. Fóris G, Dezsö B, Medgyesi GA, Füst G: Effect of angiotensin II on macrophage functions. Immunology 1983;48:529-535.
41. Weinstock JV, Kassab JT: Angiotensin II stimulation of granuloma macrophage phagocytosis and actin polymerization in murine schistosomiasis mansoni. Cell Immunol 1984;89:46-54.
42. Mauer SM, Fish AJ, Blau EB, Michael AF: The glomerular mesangium. I. Kinetic studies of macromolecular uptake in normal and nephrotic rats. J Clin Invest 1972;51:1092-1101.
43. Keane WF, Raij L: Relationship among altered glomerular barrier permselectivity, angiotensin II and mesangial uptake of macromolecules. Lab Invest 1985;52: 599-604.
44. Diamond JR, Karnovsky MJ: Focal and segmental glomerulosclerosis following a single intravenous dose of puromycin aminonucleoside. Am J Pathol 1986;122: 481-487.
45. Fogo A, Yoshida Y, Glick AD, Homma T, Ichikawa I: Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest 1988;82:322-330.
46. Grond J, Koudstaal J, Elema JD: Mesangial function and glomerular sclerosis in rats with aminonucleoside nephrosis. Kidney Int 1985;27:405-410.
47. Klahr S, Schreiner G, Ichikawa I: The progression of renal disease. N Engl J Med 1988;318:1657-1666.
48. Blantz RC, Konnen KS, Tucker BJ: Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat. J Clin Invest 1976;57: 419-434.
49. Eisenback GM, Van Liew JB, Boylan JW, et al.: Effect of angiotensin on the filtration of protein in the rat kidney: A micropuncture study. Kidney Int 1975;8:80-87.
50. Brandt JL, Gruhn JG: Effect of renin on proteinuria and PAH clearance at low plasma levels. Am J Physiol 1948;153:458-464.
51. Bohrer MP, Deen WM, Robertson CR, Brenner BM: Mechanism of angiotensin II-induced proteinuria in the rat. Am J Physiol 1977;233:F13-F21.
52. Pelayo JC, Quan AH, Shanley PF: Angiotensin II control of the renal microcirculation in rats with reduced renal mass. Am J Physiology 1990;258:F414-F422.
53. Yoshioka T, Rennke HG, Salant DJ, Deen WM, Ichikawa I: Role of abnormally high transmural pressure in the permselectivity defect of glomerular capillary wall: A study in early passive Heymann nephritis. Circ Res 1987;61:531-538.
54. Shemesh O, Deen WM, Brenner BM, McNeely E, Myers BD: Effect of colloid volume expansion on glomerular barrier size-selectivity in humans. Kidney Int 1986;29: 916-923.
55. Remuzzi A, Perticucci E, Ruggenenti P, Mosconi L, Limonta M, Remuzzi G: Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 1991;39:1267-1273.
56. Gansevoort R, de Zeeuw D, de Jong PE: Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease. Am J Kidney Dis 1993;22:202-206.
57. Lemley K, Kriz W: Glomerular injury in analbuminemic rats after subtotal nephrectomy. Nephron 1991;59: 104-109.
58. Okuda S, Oochi N, Wakisaka M, et al.: Albuminemia is not an aggravating factor in experimental focal glomerulosclerosis and hyalinosis. J Lab Clin Med 1992;119: 245-253.
59. Eddy AA, McCulloch L, Adams J, Liu E: Interstitial neohritis induced by protein overload proteinuria. Am J Pathol 1989;135:719-733.
60. Schwartz MM, Bidani AK, Lewis EJ: Glomerular epithelial cell structure and function in chronic proteinuria induced by homologous protein-load. Lab Invest 1986;55:673-679.
61. Williams JD, Czop JK, Abramhamson DR, Davies M, Austen KF: Activation of the alternative complement pathway by isolated human glomerular basement membrane. J Immunol 1984;133:394-399.
62. Kees-Folts D, Sadow JL, Schreiner GF: Tubular catabolism of albumin is associated with the release of an inflammatory lipid. Kidney Int 1994;45:1697-1709.
63. Rustom R, Jackson MJ, Critchley M, Bone JM: Tubular metabolism of aprotonin 99 mTc and urinary ammonia: Effects of proteinuria. Miner Electrolyte Metab 1992;18:108-112.
64. Bruton CJ, Walls J, Harris KPG: Characterization of the serum factor that stimulates human cortical epithelial cells to produce fibronectin and PDGF [Abstract]. J Am Soc Nephrol 1995;6:1010A.
65. Alfrey AC, Froment DH, Hammond WS: Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis. Kidney Int 1989;36:753-759.
66. Wheeler DC, Bernard DB: Lipid abnormalities in the nephrotic syndrome: Causes, consequences and treatment. Am J Kidney Dis 1994;23:331-346.
67. Grone EF, Walli AK, Grone H-J, Miller B, Seidel D: The role of lipids in nephrosclerosis and glomerulosclerosis. Atherosclerosis 1994;107:1-13.
68. Grond J, Van Goor H, Erkelens DW, Elema JD: Glomerular sclerotic lesions in the rat: Histochemical analysis of their macromolecular and cellular composition. Virchows Arch 1986;51:521-534.
69. Van Goor H, Van Der Horst MLC, Atmosoerodjo J, Joles JA, van Tol J, Grond J: Renal apolipoproteins in nephrotic rats. Am J Pathol 1993;142:1804-1812.
70. Magil AB, Cohen AH: Monocytes and focal glomerulosclerosis. Lab Invest 1989;61:404-409.
71. Rovin BH, Tan LC: LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int 1993;43:218-225.
72. Bank N, Aynedjian HS: Role of thromboxane in impaired renal vasodilation response to acetylcholine in hypercholesterolemic rats. J Clin Invest 1992;89:1636-1642.
73. Kaplan R, Aynedjian HS, Schlondorff D, Bank N: Renal vasoconstriction caused by short-term cholesterol feeding is corrected by thromboxane antagonist or probucol. J Clin Invest 1990;86:1707-1714.
74. Williams JD, Coles GA: Proteinuria: A direct cause of renal morbidity? Kidney Int 1994;45:443-450.
75. D'Amico G, Ferrario F, Rastaldi MP: Tubulointerstitial damage in glomerular diseases: Its role in the progression of renal damage. Am J Kidney Dis 1995;26:124-132.
76. Davies RW, Staprans I, Hutchison FN, Kaysen GA: Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest 1990; 86:600-605.
77. Keilani T, Schlueter WA, Levin ML: Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor. Ann Intern Med 1993;118:246-254.
78. Rosenblum NB: The mesangial matrix in the normal and sclerotic glomerulus. Kidney Int 1994;45[Suppl 45]:S73-S77.
79. Couchman JR, Beavan LA, McCarthy K: Glomerular matrix: Synthesis, turnover and role in mesangial expansion. Kidney Int 1994;45:328-335.
80. Ebihara I, Suzuki S, Nakamura T, et al.: Extracellular matrix component mRNA expression in glomeruli in experimental focal glomerulosclerosis. J Am Soc Nephrol 1993;3:1387-1397.
81. Ray PE, Bruggeman LA, Horikoshi S, Aguilera G, Klotman P: Angiotensin II stimulates human fetal mesangial cell proliferation and fibronectin biosynthesis by binding to AT1 receptors. Kidney Int 1994;45:177-184.
82. Sadoshima J, Qiu Z, Morgan JP, Izumo S: Angiotensin II and other hypertrophic stimuli mediated by G protein-coupled receptors activate tyrosine kinase, mitogen-activated protein kinase, and 90-kD S6 kinase in cardiac myocytes: The critical role of Ca(2+)-dependent signaling. Circ Res 1995;76:1-15.
83. Gibbons GH, Pratt RE, Dzau VJ: Vascular smooth muscle cell hypertrophy vs. hyperplasia. J Clin Invest 1992;90:456-461.
84. Schelling P, Fischer H, Ganten D: Angiotensin and cell growth: A link to cardiovascular hypertrophy? J Hypertens 1991;9:3-15.
85. Sadoshima J, Izumo S: Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro: Roles of phospholipid-derived second messengers. Circ Res 1993;73:424-438.
86. Kolch W, Heidecker G, Kochs G, et al.: Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 1993;364:249-252.
87. Treisman R: Ternary complex factors: Growth factor regulated transcriptional activators. Curr Opin Genet Dev 1994;4:96-101.
88. Kim SJ, Romeo D, Yoo YD, Park K: Transforming growth factor-β: Expression in normal and pathological conditions. Horm Res (Basel) 1994;42:5-8.
89. Gonzalez-Espinosa C, Garcia-Sainz JA: Protein kinase and phosphatases modulate c-fos expression in rat hepatocytes: Effects of angiotensin II and phorbol myristate acetate. Life Sci 1995;56:723-728.
90. Puri PL, Avantaggiati ML, Burgio VL, et al.: Reactive oxygen intermediates mediate angiotensin II-induced c-Jun.c-Fos heterodimer DNA binding activity and proliferative hypertrophic responses in myogenic cells. J Biol Chem 1995;270:22129-22134.
91. Wrana J, Attisano L, Wieser R, Ventura F, Massague J: Mechanism of activation of the TGF-beta receptor. Nature (Lond) 1994;370:341-347.
92. Wang T, Donahoe PK, Zervos AS: Specific interaction of type I receptors of the TGF-β family with the immunophilin FKBP-12. Science (Washington DC) 1994;265: 674-676.
93. Chen R, Miettinen PJ, Maruoka EM, Choy L, Derynck R: A WD-domein protein that is associated with and phosphorylated by the type II TGF-β receptor. Nature (Lond) 1995;377:548-552.
94. Alexandrow MG, Moses HL: Transforming growth factor β and cell cycle regulation. Cancer Res 1995;55: 1452-1457.
95. Yamaguchi K, Shirakabe K, Shibuya H, et al.: Identification of a member of the MAPKKK family as a potential mediator of TGF-β Signal transduction. Science (Washington DC) 1995;270:2008-2011.
96. Rossi P, Karsenty G, Roberts AB, et al.: A nuclear factor 1 binding site mediates the transcriptional activation of a type I collagen promoter by transforming growth factor-β. Cell 1988;52:408-414.
97. Ritzenthaler JD, Goldstein RH, Fine A, Smith BD: Regulation of the α1(I) collagen promoter via a transforming growth factor-β activation element. J Biol Chem 1993;268:13625-13631.
98. Inagaki Y, Truter S, Ramirez F: Transforming growth factor-β stimulates α2(I) collagen gene expression through a cis-acting element that contains an Sp1-binding site. J Biol Chem 1994;269:14828-14834.
99. Jimenez SA, Varga J, Olsen A, et al.: Functional analysis of human α1(I) procollagen gene promoter. Differential activity in collagen-producing and nonproducing cells and response to transforming growth factor β1. J Biol Chem 1994;269:12684-12691.
100. Alevizopoulos A, Dusserre Y, Tsai-Pflugfelder M, von der Weid T, Wahli W, Mermod N: A proline-rich TGF-β-responsive transcriptional activator interacts with histone H3. Genes Dev 1995;9:3051-3066.
101. Paquet JL, Baudouin-Legros M, Brunelle G, Meyer P: Angiotensin II-induced proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens 1990; 8:565-572.
102. Dzau V, Gibbons GH, Pratt RE: Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension (Dallas) 1991;18[Suppl 21:100-105.
103. Berk BC, Vekshtein V, Gordon HM, Tsuda T: Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension (Dallas) 1989;13: 305-314.
104. Homma T, Hoover RL, Ichikawa I, Harris RC: Angiotensin II induces hypertrophy and stimulates collagen production in cultured rat glomerular mesangial cell [Abstract]. Clin Res 1990;38:A358.
105. Wolf G, Haberstroh U, Neilson EG: Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 1992;140:95-107.
106. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-2437.
107. Wolf G, Mueller E, Stahl RA, Ziyadeh FN: Angiotensin Il-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-β. J Clin Invest 1993;92:1366-1372.
108. Riser BL, Cortes P, Zhao X, Bernstein J, Dumler F, Narins RG: Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. J Clin Invest 1992;90:1932-1943.
109. Nakamura T, Takahashi T, Mitsumine F, et al.: Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats. J Am Soc Nephrol 1995;5:1492-1497.
110. Arai M, Wada A, Isaka Y, et al.: In vivo transfection of genes for renin and angiotensinogen into the glomerular cells induced phenotypic change of the mesangial cells and glomerular sclerosis. Biochem Biophys Res Commun 1995;206:525-532.
111. Kim S, Ohta K, Hamaguchi A, et al.: Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury. Kidney Int 1994; 46:1346-1358.
112. Kim S, Ohta K, Hamaguchi A, et al.: Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension (Dallas) 1994;24:195-204.
113. Dworkin LD, Levin RI, Benstein JA, et al.: Effects of nifedipine and enalapril on glomerular injury in rats with deoxycorticosterone-salt hypertension. Am J Physiol 1990;259:F598-F604.
114. Ruiz-Ortega M, Gomez-Garre D, Alcazar R, et al.: Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis. J Hypertens 1994;12[Suppl 4]:S51-S58.
115. Isaka Y, Fujiwara Y, Ueda N, Kaneda T, Kamada T, Imai E: Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor gene into the rat kidney. J Clin Invest 1993;92: 2597-2601.
116. Naftilan AJ, Pratt RE, Dzau VJ: Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1419-1424.
117. Tanaka R, Sugiura K, Tatematsu A, Fogo A: Internephron heterogeneity of growth factors and sclerosis - modulation of platelet-derived growth factor by angiotensin II. Kidney Int 1995;47:131-139.
118. Moriyama T, Fujibayashi M, Fujiwara Y, et al.: Angiotensin II stimulates interleukin-6 release from cultured mouse mesangial cells. J Am Soc Nephrol 1995;6:95-101.
119. Suematsu S, Matsusaka T, Matsuda T, et al.: Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 1992;89:232-235.
120. Lee LK, Meyer TW, Pollock AS, Lovett DH: Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest 1995;96:953-964.
121. Nakamura T, Miller D, Ruoslahti E, Border WA: Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-β1. Kidney Int 1992;41:1213-1221.
122. Marinides GN, Groggel GC, Cohen AH, Border WA: Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy. Kidney Int 1990;37: 749-757.
123. Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa I: Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 1991;40:195-202.
124. Mignatti P: Extracellular matrix remodeling by metalloproteinases and plasminogen activators. Kidney Int 1995;47[Suppl 49]:S12-S14.
125. Baricos WH, Cortez SL, El-Dahr SS, Schnaper HW: ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int 1995;47:1039-1047.
126. Keeton M, Ahn C, Eguchi Y, Burlingame R, Loskutoff DJ: Expression of type 1 plasminogen activator in renal tissue in murine lupus nephritis. Kidney Int 1995;47: 148-157.
127. van Leeuwen RT, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G: Angiotensin II increases plasminogen activator inhibitor type I and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994;90:362-368.
128. Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potent link between the renin-angiotensin system and thrombosis. J Clin Invest 1995;95:995-1001.
129. Feener EP, Northup JM, Aiello LP, King GL: Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995;95:1353-1362.
130. Zelezna B, Rydezewski B, Lu D, et al.: Angiotensin-II induction of plasminogen activator inhibitor-1 gene expression in astroglial cells of normotensive and spontaneously hypertensive rat brain. Mol Endocrinol 1992; 6:2009-2017.
131. Ridker PM, Gaboury CL, Conlin PR, Seely GH, Wiliams GH, Vaughan DE: Stimulation of plasminogen activator inhibitor (PAI-1) in vivo by infusion of angiotensin II. Circulation 1993;87:1969-1973.
132. Wright RA, Flapan AD, Alberti KGMM, Ludlam CA, Fox KAA: Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994;24:67-73.
133. Schainnuck LI, Striker GE, Cutler RE, Benditt EP: Structural-functional correlations in renal disease. Part II: The correlations. Hum Pathol 1970;1:631-641.
134. Diamond JR, Anderson S: Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis. Am J Pathol 1990;137:1323-1332.
135. Kaneto H, Morrissey J, Klahr S: Increased expression of TGF-β1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 1993;44:313-321.
136. Sappino AP, Schurch W, Gabbiani G: Biology of Disease. Differentiation repertoire of fibroblastic cells: Expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest 1990;63:144-161.
137. Alpers CE, Hudkins KL, Floege J, Johnson RJ: Human renal cortical interstitial cells with some features of smooth muscle cells participate in tubulointerstitial and crescentic glomerular injury. J Am Soc Nephrol 1994;5:201-210.
138. Rodemann HP, Muller GA: Characterization of human renal fibroblasts in health and disease: II. In vitro growth, differentiation, and collagen synthesis of fibroblasts from kidneys with interstitial fibrosis. Am J Kidney Dis 1991;17:684-686.
139. Johnson RJ, Alpers CE, Yoshimura A, et al.: Renal injury from angiotensin II mediated hypertension. Hypertension (Dallas) 1992;19:464-474.
140. Giachelli CM, Pichler R, Lombardi D, et al.: Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. Kidney Int 1994;45:515-524.
141. Gadeau AP, Campan M, Millet D, Candresse T, Desgranges C: Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro. Arterioscler Thromb 1993;13:120-125.
142. Nikolic-Paterson DJ, Lan HY, Hill PA, Atkins RC: Macrophages in renal injury. Kidney Int 1994;45[Suppl 45]:S79-S82.
143. Schreiner GF, Cotran RS, Pardo V, Unanue ER: A mononuclear cell component to experimental immunological glomerulonephritis. J Exp Med 1978;147:369-384.
144. Holdsworth SR, Neale TJ, Wilson CB: Abrogation of macrophage-dependent injury in experimental glomerulonephritis in the rabbit. J Clin Invest 1981;68:686-698.
145. Weinstock JV, Boros DL, Gee JB, Ehrinpreis MN: The effect of SQ 14225, an inhibitor of angiotensin I converting enzyme, on the granulomatous response to Schistosoma mansoni eggs in mice. J Clin Invest 1982; 67:931-936.
146. Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S: Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 1995;47:1285-1294.
147. Shreiner GF, Harris KP, Purkerson ML, Klar S: Immunologic aspects of acute ureteral obstruction: Immune cell infiltrate in the kidney. Kidney Int 1988;34:487-493.
148. Diamond JR, Karnovsky MJ: Focal and segmental glomerulosclerosis: Analogies to atherosclerosis. Kidney Int 1988;33:917-924.
149. Kowala MC, Grove RI, Aberg G: Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters: Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis 1994;108:61-72.
150. Schuh JR, Blehm DJ, Frierdich GE, McMahon EG, Blaine EH: Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest 1993;91:1453-1458.
151. Weinstock JV, Kassab JT: Functional angiotensin II receptors on macrophages from isolated liver granulomas of murine Schistosoma mansoni. J Immunol 1984; 132:2598-2602.
152. Hahn AWA, Jonas U, Buhler FR, Resink TJ: Activation of human peripheral monocytes by angiotensin II. FEBS (Fed Eur Biol Soc) Lett 1994;347:178-180.
153. Goetzl EJ, Klickstein LB, Watt KWK, Wintroub BU: The preferential human mononuclear leukocyte chemotactic activity of the substituent tetrapeptides of angiotensin II. Biochem Biophys Res Commun 1980; 97:1097-1102.
154. Morrissey J, Ishidoya S, Klahr S: Inhibition of NOS modulates the effects of enalapril on tubulointerstitial fibrosis [Abstract]. J Am Soc Nephrol 1994;5:587A.
155. Vance BA, Kelly CJ: A nephritogenic T cell clone expresses components of the renin-angiotensin system and is responsive to angiotensin II [Abstract]. J Am Soc Nephrol 1994;5:772A.
156. Keidar S, Kaplan M, Shapira C, Brook JG, Aviram M: Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: A possible role for angiotensin II. Atherosclerosis 1994; 107:71-84.
157. Greene E, Kren S, Hostetter T: Role of aldosterone in the remnant kidney [Abstract]. J Am Soc Nephrol 1994; 5:541A.
158. Hostetter TH, Rosenberg ME, Kren S, Greene E: Aldosterone induces glomerular sclerosis in the remnant kidney [Abstract]. J Am Soc Nephrol 1995;6:1016A.
159. Niimura F, Labosky PA, Kakuchi J, et al.: Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth regulation. J Clin Invest 1995;96:2947-2954.
160. Kim HS, Krege JH, Kluckman KD, et al.: 1995. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 1995;92:2735-2739.
161. Peten EP, Striker LJ, Fogo A, Ichikawa I, Patel A, Striker GE: The molecular basis of increased glomerulosclerosis after blockade of the renin angiotensin system in growth hormone transgenic mice. Mol Med 1994;1:104-115.
162. Chevalier RL, Sturgill BC, Jones CE, Kaiser DL: Morphologic correlates of renal growth arrest in neonatal partial ureteral obstruction. Pediatr Res 1987;21:338-346.
163. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-1346.
164. Tiret L, Rigat B, Visvikis S, et al.: Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma levels. Am J Hum Genet 1992;51:197-205.
165. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F: Angiotensin 1-converting enzyme in human circulating mononuclear cells: Genetic polymorphism of expression in T-lymphocytes. Biochem J 1993;290[Pt 1]:33-40.
166. Cambien F, Poirier O, Lecerf L, et al.: Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature (Lond) 1992;359:641-644.
167. Higashimori K, Zhao Y, Higaki J, et al.: Association analysis of a polymorphism of the angiotensin converting enzyme gene with essential hypertension in the Japanese population. Biochem Biophys Res Commun 1993;191:399-404.
168. Zee RY, Lou YK, Griffiths LR, Morris BJ: Association of a polymorphism of the angiotensin I-converting enzyme gene with essential hypertension. Biochem Biophys Res Commun 1992;184:9-15.
169. Bohn M, Berge KE, Bakken A, Erikssen J, Berg K: Insertion/deletion polymorphism at the locus for angiotensin 1-converting enzyme and parental history of myocardial infarction. Clin Genet 1993;44:298-301.
170. Schunkert H, Hense HW, Holmer SR, et al.: Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 1994;330:1634-1638.
171. Kupari M, Perola M, Koskinen P, Virolainen J, Karhunen PJ: Left ventricular size, mass, amd function in relation to angiotensin-converting enzyme gene polymorphism in human. Am J Physiol 1994;267:H1107-H1111.
172. Jeunemaitre X, Soubrier F, Kotelevsev YV, et al.: Molecular basis of human hypertension: Role of angiotensinogen. Cell 1992;71:169-180.
173. Hata A, Namikawa C, Sasaki M et al.: Angiotensin as a risk factor for essential hypertension in Japan. J Clin Invest 1994;93:1285-1287.
174. Katsuya T, Koike G, Yee TW, et al.: Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet 1995;345:1600-1603.
175. Kamitani A, Rakuji H, Higaki J, et al.: Enhanced predictability of myocardial infarction in Japanese by combined genotype analysis. Hypertension 1995;25: 950-953.
176. Bonnardeaux A, Davies E, Jeunemaitre X, et al.: Angiotensin II type 1 receptor gene polymorphism in human essential hypertension. Hypertension 1994;24: 63-69.
177. Tiret L, Bonnardeaux A, Poirier O, et al.: Synergic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocrdial infarction. Lancet 1994;344:910-913.
178. Yoshida H, Mitarai T, Kawamura T, et al.: Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995; 96:2162-2169.
179. Hunley TE, Julian BA, Phillips JA III, et al.: Angiotensin converting enzyme gene polymorphism: Potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 1996;49:571-577.
180. Schmidt S, Schone N, Ritz E, and the Diabetic Nephropathy Study Group: Association of ACE gene polymorphism and diabetic nephropathy? Kidney Int 1995; 47:1176-1181.
181. Marre M, Bernadet P, Gallois Y, et al.: Relationships between angiotensin I-converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 1994;43:384-388.
182. Doria A, Warram JH, Krolewski AS: Genetic predisposition to diabetic nephropathy: Evidence for a role of the angiotensin 1-converting enzyme gene. Diabetes 1994; 43:690-695.
183. Jacobson P, Tarnow L, Rossing P, et al.: The insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene predicts the progression of diabetic nephropathy during ACE inhibition in insulin dependent diabetic patients [Abstract]. J Am Soc Nephrol 1995;6:450.
184. Yoshida H, Kuriyama S, Atsumi Y, et al.: Angiotensin-I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus. Kidney Int, 1995;50:657-664.
185. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM: Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 1981;241:F85-F93.
186. Acchiardo SR, Moore LW, Cockrell S: Does low protein diet halt the progression of renal insufficiency? Clin Nephrol 1986;25:289-294.
187. Ihle BU, Becker GJ, Whitworth JA, Charlwood RA, Kincaid-Smith PS: The effect of protein restriction on the progression of renal insufficiency. N Engl J Med 1989;321:1773-1777.
188. Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR: Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 1991;324:78-84.
189. Locatelli F, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A: Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group. Lancet 1991;337:1299-1304.
190. Klahr S, Levey AS, Beck GJ, et al.: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease: Modification of diet in renal disease study group. N Engl J Med 1994;330:877-884.
191. King AJ, Levey AS: Dietary protein and renal function. J Am Soc Nephrol 1993;3:1723-1737.
192. Paller MS, Hostetter TH: Dietary protein increase plasma renin and reduces pressor reactivity to angiotensin II. Am J Physiol 1986;251:F34-F39.
193. Krishna GG, Kapoor SC: Preservation of renal reserve in chronic renal disease. Am J Kidney Dis 1991;17:18-24.
194. Hutchison FN, Martin VI, Jones H Jr, Kaysen G: Differing actions of dietary protein and enalapril on renal function and proteinuria. Am J Physiol 1990;258: F126-F132.
195. Ruilope LM, Casal MC, Praga M, et al.: Additive antiproteinuric effect of converting enzyme inhibition and a low protein intake. J Am Soc Nephrol 1992;3:1307-1311.
196. Fregly MJ, Rossi F, Van Bergen P, Brummermann M, Cade JR: Effect of chronic treatment with losartan potassium (DuP 753) on the elevation of blood pressure during chronic exposure of rats to cold. Pharmacology 1993;46:198-205.
197. Aguilera G, Kiss A, Sunar-Akbasak B: Hyperreninemic hypoaldosteronism after chronic stress in the rat. J Clin Invest 1995;96:1512-1519.
198. Esnault VL, Potiron-Josse M, Tetra A, Ginet JD, Le Carrer D, Guenel J: Captopril but not acebutolol, prazosin or indomethacin decreases postexercise proteinuria. Nephron 1991;58:437-442.
199. Cosenzi A, Carraro M, Sacerdote A, et al.: Involvement of the renin angiotensin system in the pathogenesis of postexercise proteinuria. Scand J Urol Nephrol 1993; 27:301-304.
200. Mittleman KD, Zambraski EJ: Exercise-induced proteinuria is attenuated by indomethacin. Med Sci Sports Exerc 1992;24:1069-1074.
201. Miura S, Ideishi M, Sakai T, et al.: Angiotensin II formation by an alternative pathway during exercise in humans. J Hypertens 1994;12:1177-1181.
202. Aldigier JC, Huang H, Dalmay F, et al.: Angiotensin-converting enzyme inhibition dose not suppress plasma angiotensin II increase during exercise in humans. J Cardiovasc Pharmacol 1993;21:289-295.
203. Cornacoff JB, Hebert LA, Sharma HM, Bay WH, Young DC: Adverse effect of exercise on immune complex-mediated glomerulonephritis. Nephron 1985;40:292-296.
204. Heifets M, Davis TA, Tegtmeyer E, Klahr S: Exercise training ameliorates progressive renal disease in rats with subtotal nephrectomy. Kidney Int 1987;32:815-820.
205. The CONSCENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987;316:1429-1435.
206. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
207. The SOLVD Investigators: Effect of captopril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions N Engl J Med 1992;327:685-691.
208. The SAVE Investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327:669-677.
209. Pfeffer MA, Lamas GA, Vaughan DE, et al.: Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988;319: 80-86.
210. Sharpe N, Smith H, Murphy J, Greaves S, Hart H, Gamble G: Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting enzyme inhibition. Lancet 1991;337:872-876.
211. St. John Sutton M, Pfeffer MA, Plappert T, et al.: Quantitative two dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction: The protective effects of captopril. Circulation 1994;89:68-75.
212. Falkenhahn M, Franke F, Bohle RM, et al.: Cellular distribution of angiotensin converting enzyme after myocardial infarction. Hypertension (Dallas) 1995;25: 219-226.
213. Pfeffer MA: ACE inhibition in acute myocardial infarction. N Engl J Med 1995;332:118-119.
214. Ambrosioni E, Borghi C, Magnani B: The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995;332:80-85.
215. Kober L, Torp-Pedersen C, Carlsen JE, et al.: A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333:1670-1676.
216. Lopes-Ovejero JA, Saal SDF, D'Angelo WA, Cheigh JS, Stengel KH, Laragh JH: Reversal of vascular and renal crisis of scleroderma by oral angiotensin-converting enzyme blockade. N Engl J Med 1979;300:1417-1419.
217. Liou H, Huang T, Campese VM: Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases. Nephron 1995; 69:41-48.
218. Praga M, Hernandez E, Montoyo C, Andres A, Ruilope LM, Rodicio JL: Long-term beneficial effect of angiotensin-converting enzyme inhibition in patient with nephrotic proteinuria. Am J Kidney Dis 1992;20:240-248.
219. Zucchelli P, Zuccala A, Borghi M, et al.: Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992;42: 452-458.
220. Chan JCN, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R: Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: One year analysis. Br Med J 1992;24:981-985.
221. Slataper R, Vicknair N, Sadler R, Bakris GL: Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med 1993;153:973-980.
222. Mimran A, Ribstein J: Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases. Am J Hypertens 1994;7:73S-81S.
223. Navar LG, Champion WJ, Thomas CE: Effects of calcium channel blockade on renal vascular resistance responses to changes in perfusion pressure and angiotensin-converting enzyme inhibition in dogs. Circ Res 1986;58:874-881.
224. Dworkin LD, Benstein JA, Parker M, Tolbert E, Feiner HD: Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 1993;43:808-814.
225. Tolins JP, Raij L: Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomerular injury. Hypertension (Dallas) 1990;16:452-461.
226. Brunner FP, Bock HA, Hermle M, Thiel G, Mihatsch MJ: Control of hypertension by verapamil enhances renal damage in a rat remnant kidney model. Nephrol Dial Transplant 1991;6:420-427.
227. Fogo A, Sakai T, Berliner KTN, Ichikawa I: Insidious nature of diabetic nephropathy: Glomerular sclerosis can develop with normal serum creatinine [Abstract]. Lab Invest 1991;64:A97.
228. Weir MR: Impact of age, race, and obesity on hypertensive mechanisms and thrapy. Am J Med 1991;90:38-14S.
229. Allan G, Cambrige D, Hardy GW, Follentant MJ, Ford A, Oliver PL: BW A575C: A novel antihypertensive drug with ACE inhibition and beta blocking properties. J Hypertens 1986;4[Suppl 6]:131-133.
230. Fournie-Zaluski MC, Gonzalez W, Turcaud S, Pham I, Roques BP, Michel JB: Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: A potential therapeutic approach in hypertension. Proc Natl Acad Sci USA 1994;91:4072-4076.
231. Sobotka PA, Brottman MD, Weitz Z, Birnbaum AJ, Skosey JL, Zarling EJ: Elevated breath pentane in heart failure reduced by free radical scavenger. Free Radical Biol Med 1993;14:643-647.
232. van Gilst WH, de Graeff PA, Wesseling H, de Langen CD: Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: A comparison of captopril, enalapril and HOE 498. J Cardiovasc Pharmacol 1986;8:722-728.
233. Suzuki H, Matsumori A, Matoba Y, et al.: Enhanced expression of superoxide dimutase messenger RNA in viral myocarditis: An SH-dependent reduction of its expression and myocardial injury. J Clin Invest 1993; 91:2727-2733.
234. Tanaka R, Kon V, Yoshioka T, Ichikawa I, Fogo A: Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int 1994;45:537-543.
235. Urata H, Strobel F, Ganten D: Widespread tissue distribution of human chymase. J Hypertens 1994; 12[Suppl 9]:S17-S22.
236. Chansel D, Bizet T, Vandermeersch S, Pham P, Levy B, Ardaillou R: Differential regulation of angiotensin II and losartan binding sites in glomeruli and mesangial cells. Am J Physiol 1994;266:F384-F393.
237. Chiu AT, McCall DE, Roscoe WA: [125I]EXP985: A highly potent and specific nonpeptide radioligand antagonist for the ATI angiotensin receptor. Biochem Biophys Res Commun 1992;188:1030-1039.
238. Chansel D, Vandermeersch S, Pham P, Ardaillou R: Characterization of [3H]losartan receptors in isolated rat glomeruli. Eur J Pharmacol Mol Pharmacol 1993; 247:193-198.
239. Chansel D, Badre L, Czekalski S, et al.: Intrinsic properties of the nonpeptide angiotensin II antagonist losartan in glomeruli and mesangial cells at high concentrations. J Pharmacol Exp Ther 1993;265:1534-1543.
240. Ichikawa I: Will angiotensin II receptor antagonists be renoprotective in humans? Kidney Int, 1996;50:684-692.
241. Kon V, Fogo A, Ichikawa I: Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993;44:545-500.
242. Toto R: Losartan is an effective well-tolerated and sage antihypertensive in patients with chronic renal insufficiency [Abstract]. Satellite Symposium of the Internal Congress of Nephrology: A New Class for the Treatment of Hypertension, Madrid, July 7, 1995.
243. Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE: Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994;12[Suppl]:S37-S42.
244. Rousseau A, Michaud A, Chauvet M-T, Lenfant M, Corvol P: The hemoregulatory peptide N-Acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-coverting enzyme. J Biol Chem 1995;270:3656-3661.
245. Wei L, Clauser E, Alhenc-Gelas F, Corvol P: The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem 1992;267:13398-13405.